Showing results (41-50 of 280) with videos related to
Sort By:
Pageof 28
Cancer Management and Research|January 18, 2013
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone diseaseMichael R Harrison, Terence Z Wong, Andrew J Armstrong, et al.Clinical Genitourinary Cancer|September 6, 2024
Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical RationaleCora N Sternberg, Stephen J Freedland, Daniel J George, et al.Bioorganic & Medicinal Chemistry Letters|April 8, 2020
Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancerSubha Bakthavatsalam, Petpailin Wiangnak, Daniel J George, et al.Cancer|September 6, 2022
Racial disparities in Black men with prostate cancer: A literature reviewJames W Lillard, Kelvin A Moses, Brandon A Mahal, et al.Clinical Genitourinary Cancer|June 8, 2007
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinomaMohit Kasibhatla, Peter Steinberg, Jeffrey Meyer, et al.Future Oncology (London, England)|January 11, 2020
Understanding the adverse event experience in the S-TRAC adjuvant trial of sunitinib for high-risk renal cell carcinomaSarah Yenser Wood, Joanne C Ryan, Andrew G Clair, et al.Targeted Oncology|February 15, 2018
Immune Checkpoint Blockade: The New Frontier in Cancer TreatmentJeffrey M Clarke, Daniel J George, Stacey Lisi, et al.Future Oncology (London, England)|March 7, 2025
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancerNeal D Shore, Daniel J George, Daniel E Spratt, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2005
Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancerHaojie Li, Philip W Kantoff, Jing Ma, et al.The Oncologist|October 6, 2022
The Value of Phenotypic Precision Medicine in Prostate CancerNathan M Hawkey, Amanda Broderick, Daniel J George, et al.Pageof 28